Abstract Details

Title A Retrospective Cohort Study to Assess the Clinical and Economic Burden in Treated versus Untreated People With Relapsing-remitting Multiple Sclerosis in the United States

Topic Multiple Sclerosis

Presentation(s) P2 - Poster Session 2 (11:45 AM-12:45 PM)

Poster/Presentation
Number 20-001

Objective To evaluate the real-world clinical and economic burden in treated versus untreated people with relapsing-remitting multiple sclerosis (pwRRMS) in the United States (US).

Background Disease-modifying therapies (DMTs) are central to managing RRMS and improving outcomes. However, despite the availability of multiple treatment options, many pwRRMS remain untreated, and real-world evidence comparing treated versus untreated in pwRRMS is limited.

Design/Methods This retrospective cohort study was conducted using a US-based claims database (07/01/2020–06/30/2023). PwRRMS were identified using a validated algorithm and segregated into treated (received DMTs during 1-year baseline) and untreated (no DMTs during 1-year baseline) cohorts. Demographics, comorbidities, healthcare resource utilization (HCRU), and healthcare costs (adjusted to 2023 US-dollars) were analyzed.

Results The final cohorts included 8,763 treated (mean±standard deviation [SD]: 48.9±10.7 years; 73.6% female) and 5,473 untreated (53.5±13.9 years; 78.3% female) pwRRMS. The mean±SD Charlson Comorbidity Index score (0.5±1.1 vs. 1.0±1.7) and infections (50.6% vs. 54.3%) were significantly lower in the treated versus untreated cohorts (P<0.001). The top three MS-related comorbidities in the treated versus untreated cohorts were malaise/fatigue (23.9% vs. 28.2%), depression (16.7% vs. 19.9%), and burning/numbness/tingling (13.7% vs. 20.5%; all P<0.001). At follow-up, the treated cohort had a significantly lower rate of hospitalizations (4.3% vs. 9.7%) and emergency department (ED) visits (16.2% vs. 24.1%; all P<0.001), and mean number of physician visits (10.9 vs. 12.7; P=0.002) versus the untreated cohort. The mean all-cause costs of hospitalizations ($1,621 vs. $3,473) and ED visits ($365 vs. $617) were lower in the treated versus untreated cohorts (P<0.001). The most common risk factors for not receiving DMT were stroke (odds-ratio: 1.85 [95% CI: 1.5–2.2]) and fibromyalgia/myositis (1.9 [1.6–2.1]).

Conclusions The untreated cohort had a higher comorbidity burden and medical costs, and greater HCRU, versus the treated cohort, highlighting the potential clinical and economic benefits of treatment whilst underscoring the continued unmet need in the untreated pwRRMS.

Authors/Disclosures
Lita Araujo, PhD (Sanofi Genzyme) PRESENTER	Dr. Araujo has received personal compensation for serving as an employee of Sanofi Genzyme.
Nupur Greene	Nupur Greene has nothing to disclose.
MANAV DAS, MBBS	Dr. DAS has nothing to disclose.
Joshua Chang, MD, PhD	Dr. Chang has nothing to disclose.
Jaja Sangbana, PhD	Mr. Sangbana has received personal compensation for serving as an employee of Sanofi. Mr. Sangbana has stock in Sanofi.
Marian H. Tarbox	Ms. Tarbox has nothing to disclose.
Melinda L. Rossi, MPH	Ms. Rossi has nothing to disclose.
Michael Broder, MD	Dr. Broder has received personal compensation for serving as an employee of ADVI Health. Dr. Broder has received personal compensation for serving as an employee of PHAR.

��ɫ��

��ɫ��